WSSAAI 2022 Northwest Allergy Forum

October 8, 2022 to October 9, 2022

The Northwest Allergy Forum is a CME educational meeting jointly provided by the American College of Allergy, Asthma & Immunology and the Oregon and Washington Societies of Allergy, Asthma & Immunology. The program is a two-day event with speakers covering a range of topics such as asthma, eczema, food allergy, vocal cord dysfunction and research developments.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of American College of Allergy, Asthma & Immunolgy and Washington State Society of Allergy, Asthma & Immunology (WSSAAI). The American College of Allergy, Asthma & Immunolgy is accredited by the ACCME to provide continuing medical education for physicians.”

The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 8 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity

The American College of Allergy, Asthma & Immunology (ACAAI) is a provider, approved by the California Board of Registered Nursing, Provider Number CEP17239, for 8 contact hours.

Commercial Support
This activity is supported in part by independent medical education grants from Biocryst and CSL Behring.

Target Audience

Practicing allergists
Allied health professionals

Learning Objectives

Upon completion of this activity the participant should be able to:

1. Identify the most effective medical treatments for CRS

2. Assess the benefits and limitations of the available treatments for HAE

3. Use clinical, laboratory, and genetic features to formulate a treatment regimen for CVID that addresses both immune deficiency and immune dysregulation features of the disease.

4. Identify advantages and disadvantages of all methods of food allergy treatment

Additional information

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months. The ACCME defines an “ineligible company” as companies whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. Examples of such organizations include:

•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers

The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All relevant financial relationships have been mitigated.

Course summary
Available credit: 
  • 8.00 AMA PRA Category 1 Credit™
  • 8.00 Attendance
  • 8.00 CBRN
Course opens: 
Course expires: 
Event starts: 
10/08/2022 - 8:00am CDT
Event ends: 
10/09/2022 - 12:30pm CDT

Northwest Allergy Forum
October 8-9, 2022

Grand Hyatt
721 Pine Street
Seattle, WA

Saturday, October 8th 

6:45am-7:45am    Non-CME Sponsored Breakfast Program – Discovery A

6:30am-7:50am    Exhibits | Registration | Coffee Break – Princessa

NWAF General Session – Eliza Anderson Amphitheater

7:50am-8:00am    Welcome & Introduction – Mark LaShell, MD – President, WSSAAI
Session Moderator – Mark Tucker, MD – Program Chair, WSSAAI

8:00am-9:00am     Allergic Contact Dermatitis, Kevin Cook, MD

9:00am-10:00am     Diagnosis and Management of Autoimmune Complications in Patients with Immune Deficiency, Troy Torgerson, MD, PhD

10:00am-10:30am    Coffee Break | Exhibits – Princessa

10:30-11:30am     Microbiome and Eczema, Ian Myles, MD, MPH

11:30am-12:30pm    Autoinflammatory Syndromes, Lori Broderick, MD, PhD

12:30pm    Adjourn

12:30-1:30pm        WSSAAI State Society Luncheon – Discovery B
                              OSAAI State Society Luncheon – Discovery A

4:00pm-5:00pm    Non-CME Sponsored Program/Reception

Sunday, October 9th  

6:45am-7:45am    Non-CME Sponsored Breakfast Program – Discovery A

7:00am-7:50am    Exhibits | Coffee Break – Princessa

NWAF General Session – Eliza Anderson Amphitheater

7:50am-8:00am    Welcome & Introduction
Session Moderator– Daniel Petroni, MD, PhD – Associate Program Chair, WSSAAI

8:00am-9:00am        Food Allergy Update: Prevention, Oral Challenges, and Immunotherapy, Stephanie Leonard, MD

9:00am-10:00am     Advances in FPIES: Diagnosis, Emergency Care, and Long-Term Management, Stephanie Leonard, MD

10:00am-10:30am     Coffee Break | Exhibits – Princessa

10:30am-11:30am     Hereditary Angioedema – An Update on Diagnosis and Management, Marc Riedl, MD, MS

11:30am-12:30pm     Chronic Rhinosinusitis and Use of Biologics, Ian M. Humphreys, DO, FARS

12:30pm                     Adjourn

All identified relevant financial relationships have been mitigated.
Lori Broderick, MD
Researcher: Novartis

Kevin Cook, MD
Advisor: ALK, Sanofi

Stephanie Leonard, MD
Speaker: Aimmune Therapeutics
Advisor: Aimmune Therapeutics, DBV Technologies, Cour Pharmaceuticals Development Co., Inc.

Marc Riedl, MD, MS
Consultant: Astria, BioCryst, Biomarin, CSL Behring, Cycle Pharma, Fresenius-Kabi, Ipsen, KalVista, Pfizer, Pharming, Pharvaris, RegenexBio, Sanofi-Regeneron, Takeda
Research Support: BioCryst, Biomarin, CSL Behring, Ionis, KalVista, Pharvaris, Takeda
Speaker: CSL Behring, Grifols, Pharming, Takeda

Troy Torgerson, MD, PhD
Advisor: Pharming Healthcare, Takeda
Consultant: Horizon Therapeutics, Takeda

Dan Petroni, MD
Consultant: Jubilant Hollister-Stier, Takeda
Speaker: AstraZeneca

Ted Song, DO
Consultant: Genentech
Speaker: AstraZeneca, Boehringer -Ingelheim

The following have no relevant financial relationships to disclose:
Ian M. Humphreys, DO, FARS
Ian A. Myles, MD, MPH
Mark LaShell, MD
Mark Tucker, MD
Mary Lasley, MD
Karol Anderson

Available Credit

  • 8.00 AMA PRA Category 1 Credit™
  • 8.00 Attendance
  • 8.00 CBRN
Please login or create an account to take this course.